<DOC>
	<DOCNO>NCT02542787</DOCNO>
	<brief_summary>Phase II Proof concept study Multiple Sclerosis ( MS ) patient spasticity .</brief_summary>
	<brief_title>Study VSN16R Treatment Spasticity Multiple Sclerosis</brief_title>
	<detailed_description>Single dose escalation follow multiple fix dose administration assess short term safety determine whether spasticity improves .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>3- ( 5-dimethylcarbamoylpent-1-enyl ) -N- ( 2-hydroxy-1-methylethyl ) benzamide</mesh_term>
	<criteria>Have confirm diagnosis MS Have Expanded Disability Status Scale ( EDSS ) â‰¤ 6.5 screening . Spasticity due MS least 3 month duration minimum mean score &gt; /=2 mASH Acute MS relapse require treatment steroid within 30 day screen . Initiation discontinuation MS disease modify treatment ( DMT ) within 30 day screen . Receiving medication would potentially interfere action study medication outcome variable Significant renal hepatic abnormality Previous history significant medical disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MS</keyword>
	<keyword>Spasticity</keyword>
	<keyword>VSN16R</keyword>
</DOC>